Cure My Disease

Don't miss your cure!

 Log in / Sign up

15-Minute MRI could spot hidden cancers in BRCA carriers

NCT ID NCT02462460

Diagnosis Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests a rapid MRI scan that takes about 15 minutes to image the pancreas and ovaries, compared to the usual 30-45 minutes per organ. The goal is to see if this faster scan can produce high-quality images that could one day be used to screen for pancreatic and ovarian cancers in people with BRCA mutations. Participants are BRCA carriers aged 30 and older who are already scheduled for a screening breast MRI. The researchers will compare different MRI techniques to find the best balance of speed and image quality.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI (magnetic resonance imaging)
What this could lead to
If successful, this could lead to a quick, 15-minute MRI screening tool for pancreatic and ovarian cancers in people with BRCA mutations, potentially catching cancers earlier.
What could go wrong
This is a small pilot study focused on image quality, not on detecting cancer directly. The technique may not prove accurate enough for widespread screening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

63 people

The number who actually took part.

Started

Jun 2015

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

MSKCC clinics

Ages

30 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

A minimum of 5 and maximum of 60 evaluable patients will be imaged on this study. Description of the subject inclusion and exclusion criteria are listed below. Inclusion Criteria: * BRCA 1 or 2 mutation * Age ≥ 30 * Patients scheduled to undergo screening breast MRI with contrast Exclusion Criteria: * Patients with known breast cancer * Patients unable to complete their scheduled breast MRI * Patients with prior pancreatic surgery or cancers * Patients with prior ovarian cancer or surgery involving removal of one or both ovaries * Patients with prior abdominal or pelvic surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Screening breast mri in patients who are BRCA mutation carriers are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Screening breast mri in patients who are BRCA mutation carriers

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States